The immunobiology of pancreatic islet transplantation

Advances in Experimental Medicine and Biology

Volumn 552, Issue , 2004, Pages 154-169

  Coulombe, Marilyne ^a   Gill, Ronald G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD4 ANTIGEN; CYTOKINE; T LYMPHOCYTE RECEPTOR;

ALLOGRAFT; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGENICITY; AUTOIMMUNE DISEASE; DONOR; GRAFT REJECTION; HUMAN; IMMUNOBIOLOGY; IMMUNOGENICITY; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; STEM CELL; SURVIVAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; XENOGRAFT;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; ISOANTIGENS; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, BIOLOGICAL; T-LYMPHOCYTES;

EID: 11844269938     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (154)

1. Eisenbarth GS. Type I diabetes mellitus: A chronic autoimmune disease. N Engl J Med 1986; 314:1360-1368.
2. Kennedy WR, Navarro X, Goetz FC et al. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990; 322:1030-7.
3. Fioretto PF, Steffes MW, Sutherland DER et al. Reversal of lesions of diabetic neuropathy after pancreas transplantation. N Engl J Med 1998; 339:69-75.
4. Gross CR, Limwattananon C, Matthees BJ. Quality of life after pancreas transplantation: A review. Clin Transplantation 1998; 12:351-361.
5. Pearce IA, Ilango B, Sells RA et al. Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant. Br J Opthalmol 2000; 84:736-740.
6. Gray BN, Watkins E. Prevention of vascular complications of diabetes by pancreatic islet transplantation. Arch Surg 1976; 111:254-257.
7. Federlin K, Bretzel RG. The effect of islet transplantation on complications in experimental diabetes of the rat. World J Surg 1984; 8:16-178.
8. Woehrle W, Spitzer D, Linn T et al. The effect of early islet transplantation on prevention of nephropathy in the spontaneously diabetic BB rat. Transplant Proc 1990; 22:819-920.
9. Robertson RP, Davis C, Larsen J et al. Pancreas and islet transplantation for patients with diabetes. Diabetes Care 2000; 23:112-116.
10. Scharp DW, Lacy PE, Santiago JV et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation 1991; 51:76-85.
11. Ricordi C, Tzakis AG, Carroll PB et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992; 53:407-414.
12. Warnock GL, Kneteman NM, Ryan EA et al. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992; 35:89-95.
13. Gores PF, Najarian JS, Stephanian E et al. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 1993; 341:19-21.
14. Hering BJ. International islet transplant registry. Newsletter #8. University of Minnesota 1999.
15. Shapiro AMJ, Lakey JRT, Ryan EA et al. Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230-8.
16. Terada M, Lennartz K, Mullen Y. Allogeneic and syngeneic pancreas transplantation in nonobese diabetic mice. Transplant Proc 1987; 19:960.
17. Wang Y, Pontesili O, Gill RG et al. The role of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc Natl Acad Sci USA 1991; 88:527-531.
18. Wang T, Singh B, Warnock GL et al. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 1992; 41:114-117.
19. Naji A, Silvers W, Kimura H et al. Influence of islet and bone marrow transplantation on the diabetes and immunodeficiency of BB rats. Metabolism 32 Suppl 1983; 1:62-68.
20. Sutherland DER, Sibley R, Xu XZ et al. Twin-to-twin pancreas transplantation: Reversal and reenactment of the pathogenesis of type I diabetes. Transplant Assoc Am Physicians 1984; 97:80-87.
21. Tyden G, Reinholt FP, Sundkvist G et al. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996; 335:860-863.
22. Stegall MD, Lafferty KJ, Kam I et al. Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation 1996; 61(8):1272-1274.
23. Medawar PB. The Uniqueness of the Individual. New York: Basic Books, 1957.
24. Snell GD. The homograft reaction. Annu Rev Microbiol 1957; 11:439-458.
25. Batchelor J, Welsh K, Burgos H. Transplantation antigens per se are poor immunogens within a species. Nature 1978; 273:54-56.
26. Lafferty KL, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975; 53:27-42.
27. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970; 169:1042-1049.
28. Talmage D, Woolnough J, Hemmingsen H et al. Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s). Proc Natl Acad Sci USA 1977; 74:1610-1614.
29. June CH, Ledbetter JA, Linsley PS et al. Role of the CD28 receptor in T-cell activation. Immunol Today 1990; 11:211-216.
30. Linsley PS, Brady W, Urnes M et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174:561-69.
31. Grewal IS, Foellmer HG, Grewal KD et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996; 273:1864-1867.
32. Schwartz RH. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065-1068.
33. Damle NK, Klussman K, Linsley PS et al. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol 1992; 148:1985-1992.
34. Van Seventer GA, Shimizu Y, Horgan KJ et al. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990; 144:4579-4586.
35. Bachmann MF, McKall-Faienza K, Schmits R et al. Distinct roles for LFA-1 and CD28 during activation of naive T cells: Adhesion versus Costimulation. Immunity 1997; 7:549-557.
36. Ni HT, Deeths MJ, Li W et al. Signaling pathways activated by leukocyte function-associated Ag-1- dependent costimulation. J Immunol 1999; 162(9):5183-9.
37. Nabavi H, Freeman GJ, Gault A et al. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992; 360:266-268.
38. Lafferty KJ, Prowse SJ, Simeonovic CJ. Immunobiology of tissue transplantation: A return to the passenger leukocyte concept. Annu Rev Immunol 1983; 1:143-173.
39. Lafferty K, Bootes A, Dart G et al. Effect of organ culture on the survival of thyroid allografts in mice. Transplantation 1976; 22:138-149.
40. Bowen K, Andrus L, Lafferty K Successful allotransplantation of mouse pancreatic islets to nonimmunosuppressed recipients. Diabetes 1980; 29(Suppl. 1):98-104.
41. Coulombe M, Gill RG. Tolerance induction to cultured islet allografts. I Characterization of the tolerant state. Transplantation 1994; 57(8):1195-1200.
42. Haug CE, Gill RG, Babcock SK et al. Cyclosporine-induced tolerance requires antigens capable of initiating an immune response. J Immunol 1987; 139:2947-2949.
43. Simeonovic CJ, Prowse SJ, Lafferty KJ. Survival and function of islet allografts in outbred mice. Transpl Proceed 1986; 18:316-318.
44. Lacy P, Davie J, Finke E. Prolongation of islet allograft survival following in vitro culture (24°C) and a single injection of ALS. Science 1979; 204:312-313.
45. Faustman D, Hauptfeld V, Lacy P et al. Prolongation of murine islet allograft survival by pretreatment of islets with antibody directed to Ia determinants. Proc Natl Acad Sci USA 1981; 78:5156-5159.
46. Morrow C, Sutherland D, Steffes M et al. Lack of donor-specific tolerance in mice with established anti-Ia-treated islet allografts. Transplantation 1983; 36:691-694.
47. Faustman D, Steinman R, Gebel H et al. Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc Natl Acad Sci USA 1984; 81:3864-3868.
48. Lau H, Reemtsma K, Hardy M. Prolongation of rat islet allograft survival by direct ultraviolet irradiation of the graft. Science 1984; 223:607-608.
49. La Rosa F. Abrogation of mouse pancreatic islet allograft rejection by a four-day culture. Transplantation 1988; 46(1):330-333.
50. Hegre O, Hickey G, Marshall S et al. Modification of allograft immunogenicity in perinatal islets isolated and purified in vitro. Transplantation 1984; 37(3):227-233.
51. La Rosa F, Talmage D. The abrogation of thyroid allograft rejection by culture in acid medium. Transplantation 1987; 44:592.
52. Hullett DA, Landry AS, Leonard DK et al. Enhancement of thyroid allograft survival following organ culture. Transplantation 1989; 47:24-27.
53. Jacobs B. Ovarian allograft survival. Transplantation 1974; 18:454.
54. Ramrakha P, Sharp R, Yeoman H et al. The influence of MHC-compatible and MHC-incompatible antigen-presenting cells on the survival of MHC-compatible cultured murine keratinocyte allografts. Transplantation 1989; 48:676-680.
55. La Rosa FG, Talmage DW. Major histocompatibility complex antigen expression on parenchymal cells of thyroid allografts is not by itself sufficient to induce rejection. Transplantation 1990; 49:605-609.
56. Batchelor JR, Welsh KI, Maynard A et al. Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity. I. Retransplantation of (AS x AUG) F1 kidneys into secondary AS recipients. J Exp Med 1979; 150:455-464.
57. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155:31-41.
58. Bowen K, Prowse S, Lafferty K. Reversal of diabetes by islet transplantation: Vulnerability of the established allograft. Science 1981; 213:1261-1262.
59. Vesole D, Dart G, Talmage D. Rejection of stable cultured allografts by active or passive (adoptive) immunization. Proc Natl Acad Sci USA 1982; 79:1626-1628.
60. Markmann J, Lo D, Naji A et al. Antigen presenting function of class II MHC expressing pancreatic beta cells. Nature 1988; 336:476-479.
61. Lo D, Burkly L, Widera G et al. Diabetes and tolerance in transgenic mice expressing class II MHC molecules in pancreatic beta cells. Cell 1988; 53:159-168.
62. Coulombe M, Yang H, Guerder S et al. Tissue Immunogenicity. The role of MHC antigen and the lymphocyte costimulator B7-1. J Immunol 1996; 157:4790-4795.
63. Gill RG, Wolf L. Immunobiology of cellular transplantation. Cell Transplant 1995; 4(4):361-370.
64. Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970; 2:550.
65. Auchincloss HJ. Xenografting: A review. Transplant Rev 1990; 4(1):14-27.
66. Sachs DH, Bach FH. Immunology of xenograft rejection. Human Immunol 1990; 28:245-251.
67. Platt JL, Bach FH. The barrier to xenotransplantation. Transplantation 1991; 52(6):937-947.
68. Logan JS. Prospects for xenotransplantation. Curr Opin in Immunol 2000; 12:563-568.
69. Galili U. Interaction of the natural anti-Gal antibody with a-galactsyl epitopes: A major obstacle for xenotransplantation in humans. Immunol Today 1993; 14:480-482.
70. Gill RG. Direct and indirect pathways of immunity to pancreatic islet transplants. Transplant Rev 1998; 12:85-95.
71. Hamelmann W, Gray DWR, Cairns TDJ et al. Immediate destruction of xenogeneic islets in a primate model. Transplantation 1994; 58:1109-1114.
72. Galili U, Tibell A, Samuelsson B et al. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters. Transplantation 1995; 59(11):1549-1556.
73. Gill R, Wolf L, Daniel D et al. CD4 T cells are both necessary and sufficient for islet xenograft rejection. Transplant Proc 1994; 26:1203.
74. Lafferty KJ, Warren HS, Woolnough JA et al. Immunological induction of T lymphocytes: Role of antigen and the costimulator. Blood Cells 1978; 4:395-404.
75. Alter BJ, Bach FH. Cellular basis of the proliferative response of human T cells to mouse xenoantigens. J Exp Med 1990; 171:333-338.
76. Moses RD, Winn HJ, Auchincloss HJ. Evidence that multiple defects in cell-surface molecule interactions across species differences are responsible for diminished xenogeneic T cell responses. Transplantation 1992; 53(1):203-209.
77. Sprent J. The thymus and T cell tolerance. Today's Life Sciences 1991; 3(12):14-20.
78. Swain SL. T cell subsets and the recognition of MHC class. Immunol Rev 1983; 74:129-142.
79. Simon AR, Warrens AN, Sykes M. Efficacy of adhesive interactions in pig-to human xenotransplantation. Immunol Today 1999; 20:323-330.
80. von Hoegen P, Miceli MC, Tourvieille B et al. Equivalence of human and mouse CD4 in enhancing antigen responses by a mouse class II-restricted T cell hybridoma. J Exp Med 1989; 170:1879-1886.
81. Vignali DAA, Moreno J, Schiller D et al. Species-specific binding of CD4 to the b2 domain of major histocompatibility complex class II molecules. J Exp Med 1992; 175:925-932.
82. Barzaga-Gilbert E, Grass D, Lawrence S et al. Species specificity and augmentation of responses to class II major histocompatibility complex molecules in human CD4 transgenic mice. J Exp Med 1992; 175:1707-1715.
83. Irwin MJ, Heath WR, Sherman LA. Species-restricted interactions between CD8 and the a3 domain of class I influence the magnitude of the xenogeneic response. J Exp Med 1989; 170:1091-1101.
84. Kalinke U, Arnold B, Hammerling GJ. Strong xenogeneic HLA response in transgenic mice after introducing an a3 domain into HLA B27. Nature 1990; 348:642-644.
85. Alter BJ, Bach FH. Lymphocyte reactivity in vitro 1. Cellular reconstitution of purified lymphocyte response. Cell Immunol 1970; 1:207-18.
86. Collins MKL. Species specificity of interleukin 2 binding to individual receptor components. Eur J Immunol 1989; 19:1517-1520.
87. Greenstein JL, Foran JA, Gorga JC et al. The role of T cell accessory molecules in the generation of class II-specific xenogeneic cytolytic T cells. J Immunol 1986; 136(7):2358-2363.
88. Golding H, Singer A. Role of accessory cell processing and presentation of shed H-2 alloantigens in allospecific cytotoxic T lymphocyte responses. J Immunol 1984; 133:597.
89. Stock PG, Ascher NL, Chen S et al. Evidence for direct and indirect pathways in the generation of the alloimmune response against pancreatic islets. Transplantation 1991; 52:704-709.
90. Benichou G, Takizawa PA, Oslon CA et al. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 1992; 175:305-308.
91. Fangmann J, Dalchau R, Fahre J. Rejection of skin allografts by indirect allorecognition of donor class I MHC peptides. J Exp Med 1992; 175:1521.
92. Coulombe M, Gill RG. Tolerance induction to cultured islet allografts. II. Status of anti-donor reactivity in tolerant animals. Transplantation 1994; 57(8):1201-1207.
93. Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994; 15(1):32-38.
94. Gill RG, Coulombe M, Lafferty KJ. Pancreatic islet allograft immunity and tolerance: The two-signal hypothesis revisited. Immunol Rev 1996; 149:75-96.
95. Yoshizawa K, Yano A. Mouse T lymphocytes proliferative responses specific for human MHC products in mouse anti-human xenogeneic MLR. J Immunol 1984; 132(6):2820-2829.
96. Brunswick M, Lake P. Functional interactions of human and murine lymphoid cells. Cell Immunol 1986; 103:441.
97. Pierson III RN, Winn HJ, Russell PS et al. Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. J Exp Med 1989; 170:991-996.
98. Mandel TE, Koulmanda M. The survival of xeno-, allo- and isografts in NOD mice and xenografts in other strains, after immunosuppression with anti-CD4 monoclonal antibody. Diab Nutr Metab 1992; 5 (Suppl. 1):91-96.
99. Gill RG, Coulombe M. Rejection of pancreatic islet xenografts does not require CD8+ T-lymphocytes. Transplant Proc 1992; 24(6):2877-2878.
100. Gould DS, Auchincloss Jr H. Direct and indirect recognition: The role of MHC antigens in graft rejection. Immunol Today 1999; 20(2):77-82.
101. Shizuru JA, Gregory AK, Chao CTB et al. Islet allograft survival after a single course of treatment of recipient with antibody to L3T4. Science 1987; 237:278-280.
102. Hao L, Wang Y, Gill RG et al. Role of the L3T4+ T cell in allograft rejection. J Immunol 1987; 139:4022-4026.
103. Gill RG, Rosenberg AS, Lafferty KJ et al. Characterization of primary T cell subsets mediating rejection of pancreatic islet grafts. J Immunol 1989; 143(7):2176-2178.
104. Ricordi C, Lacy PE, Sterbenz K et al. Low-temperature culture of human islets or in vivo treatment with L3T4 antibody produces a marked prolongation of islet human-to-mouse xenograft survival. Proc Natl Acad Sci USA 1987; 84:8080-8084.
105. Lacy PE, Ricordi C, Finke EH. Effect of transplantation site and aL3T4 treatment on survival of rat, hamster, and rabbit islet xenografts in mice. Transplantation 1989; 47(5):761-766.
106. Coulombe M, Yang H, Wolf LA et al. Tolerance to antigen-presenting cell-depleted islet allografts is CD4 T cell dependent. J Immunol 1999; 162:2503-2510.
107. Prowse SJ, Warren HS, Agostino M et al. Transfer of sensitised Lyt2+ cells triggers acute rejection of pancreatic islet allografts. Aust J Exp Biol Med Sci 1983; 61(2):181-185.
108. Wolf LA, Coulombe M, Gill RG. Donor antigen-presenting cell-independent rejection of islet xenografts. Transplantation 1995; 60(10):1164-1170.
109. Markmann JF, Bassiri H, Desai NM et al. Indefinite survival of MHC class I-deficient murine pancreatic islet allografts. Transplantation 1992; 54:1085-1089.
110. Osorio RW, Ascher NL, Jaenisch R et al. Major histocompatibility complex class I deficiency prolongs islet allograft survival. Diabetes 1993; 42:1520-1527.
111. Desai NM, Bassiri H, Kim J et al. Islet allograft, islet xenograft, and skin allograft survival in CD8+ T lymphocyte-deficient mice. Transplantation 1993; 55:718-722.
112. Gill RG, Lafferty KJ. The role of islet transplantation in the treatment of insulin-dependent diabetes mellitus. Imm Aller Clin No Amer 1989; 9(1):165-186.
113. Simeonovic CJ, Wilson JD. CD4+ T-cell depletion in mice facilitates induction of tolerance to pig proislet xenografts: A comparison of NOD and CBA/H recipient models. Diab Nutr Metab 1992; 5(Suppl. 1):133-138.
114. Gill R, Coulombe M. Islet xenografting in autoimmune diabetes. Transplant Proc 1994; 26:1140.
115. Haskins K, Portas M, Bergman B et al. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc Natl Acad Sci USA 1989; 86:8000-8004.
116. Hao L, Calcinaro F, Gill R et al. Facilitation of specific tolerance induction in adult mice by RS-61443. Transplantation 1992; 53:590-595.
117. Li H, Colson YL, Ildstad ST. Mixed allogeneic chimerism achieved by lethal and nonlethal conditioning approaches induces donor-specific tolerance to simultaneous islet allografts. Transplantation 1995; 60:523-529.
118. Wekerle T, Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation 1999; 68:459-467.
119. Fuchimoto Y, Huang CA, Yamada K et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest 2000; 105:1779-1789.
120. Posselt AM, Barker CF, Tomaszewski JE et al. Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science 1990; 249:1293-1295.
121. Pearson TC, Madsen JC, Larsen CP et al. Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation 1992; 54:475-483.
122. Cobbold SP, Adams E, Marshall SE et al. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev 1996; 149:5-33.
123. Pearson TC, Alexander DZ, Winn KJ et al. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994; 57(12):1701-1706.
124. Tran HM, Nickerson PW, Restifo AC et al. 1997. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol 159:2232-2239.
125. Lakkis FG, Konieczny BT, Saleem S et al. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997; 158:2443-2448.
126. Parker DC, Greiner DL, Phillips NE et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92:9560-9564.
127. Honey K, Cobbold SP, Waldmann H. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol 1999; 163:4805-4810.
128. Kenyon NS, Fernandez LA, Lehmann R et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999; 48:1473-1481.
129. Kenyon NS, Chatzipetrou M, Masetti M et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 1999; 96:8132-8137.
130. Nishihara M, Gotoh M, Ohzato H et al. Awareness of donor alloantigens in antiadhesion therapy induces antigen-specific unresponsiveness to islet allografts. Transplantation 1997; 64:965-970.
131. Nicolls MR, Colulombe M, Yang H et al. Anti-LFA-1 therapy induces long term islet allograft acceptance in the absence of IFN-g or IL-4. J Immunol 2000; 164:3627-3634.
132. Auersvald LA, Rothstein DM, Oliveira SC et al. Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies. Transplantation 1997; 63:1355-1369.
133. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434-438.
134. Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94:8789-8794.
135. Pearson TC, Alexander DZ, Hendrix R et al. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor-specific unresponsiveness in the murine model. Evidence for hematopoieticchimerism. Transplantation 1996; 61(7):997-1004.
136. Durham MM, Bingaman AW, Adams AB et al. Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to henopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165:1-4.
137. Lenschow DJ, Zeng Y, Thistlethwaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257(7):789-792.
138. Zeng Y, Bluestone JA, Ildstad ST et al. Long-term functional xenograft tolerance after intrathymic islet transplantation (Lewis rat → B6 mouse). Transplant Proc 1993; 25:438-439.
139. Mayo GL, Posselt AM, Barker CF et al. Prolongation of survival of donor-strain islet xenografts (rat-mouse) by intrathymic inoculation of xenogeneic islet and bone marrow cells. Transplantation 1994; 58(1):107-109.
140. Li H, El-Ezz A, Gambrell BE et al. Mixed xenogeneic chimerism and tolerance III. A nonlethal approach to induce donor-specific transplantation tolerance to simultaneous islet xenografts. Transplantation 1995; 60:59-65.
141. Elwood ET, Larsen CP, Cho HR et al. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 1998; 65:1422-1428.
142. Sablinski T, Emery DW, Monroy R et al. Long-term discordant xenogeneic (porcine-to-primate) bone marrow engraftment in a monkey treated with porcine-specific growth factors. Transplantation 1999; 67(7):972-7.
143. Carel J, Schreiber RD, Falqui L et al. Transforming growth factor b decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon g. Proc Natl Acad Sci USA 1990; 87:1591-1595.
144. Carel J-C, Sheehan KC, Schreiber RD et al. Prevention of rejection of transforming growth factor b-treated rat-to-mouse islet xenografts by monoclonal antibody to tumor necrosis factor. Transplantation 1992; 55(2):456-458.
145. Gerasimidi A, Sheehan KCF, Schreiber RD et al. Tumor necrosis factor-a prevents rejection of islet xenografts (rat to mouse). Diabetes 1993; 42:651-657.
146. Faustman D, Coe C. Prevention of xenograft rejection by masking of donor HLA class I antigens. Science 1991; 252:1700-1702.
147. Gerling IC, Serreze DV, Christianson SW et al. Intrathymic islet cell transplantation reduces beta-cell autoimmunity and prevents diabetes in NOD/Lt mice. Diabetes 1992; 41(12):1672-6.
148. Battan R, Mordes JP, Abreau S et al. Evidence that intrathymic islet transplantation does not prevent diabetes or subsequent islet graft destruction in RT6-depleted, diabetes-resistant biobreeding/Worcester rats. Transplantation 1994; 57(5):731-736.
149. Li H, Kaufman CL, Boggs SS et al. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J Immunol 1996; 156:380-388.
150. Weber CJ, Hagler MK, Chryssochoos JT et al. CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice. Cell Transplant 1997; 6(5):505-508.
151. Markees TG, Serrezc DV, Phillips NE et al. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes 1999; 48:967-974.
152. Smith RM, Mandel TE. Pancreatic islet xenotransplantation: The potential for tolerance induction. Immunol Today 2000; 21:42-8.
153. Lanza RP, Chick WL. Immunoisolation: At a turning point. Immunol Today 1997; 18:135-139.
154. Giannoukakis N, Rudert WA, Robbins PD et al. Targeting autoimmune diabetes with gene therapy. Diabetes 1999; 48:2107-2121.